S0820, Adenoma and Second Primary Prevention Trial

S0820, Adenoma and Second Primary Prevention Trial is a phase 3, randomised interventional study registered as NCT01349881 by SWOG Cancer Research Network, with a registry enrolment figure of 354 participants, started 2013-08-23 and due to reach its primary completion in 2027-09-15. Interventions recorded: Eflornithine placebo & sulindac placebo; eflornithine & sulindac placebo; Eflornithine placebo & sulindac; Eflornithine plus sulindac. Conditions listed: Colorectal Neoplasms. Primary outcome: Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC). Colorectal eligibility wording from the registry: "* History of Stage 0-III colon or rectal cancer with primary resection 1 year previously". Sites: United States. No results are recorded here; the registry entry is the source.